This project seeks to discover small molecules active in inhibiting replication of Venezuelan Equine Encephalitis Viruses (VEEV), by utilizing a high throughput screening (HTS) campaign from the Molecular Library Program Center Network (MLPCN). VEEV, an encephalitic alphavirus, is listed as a select agent for its ability to cause severe disease during epidemics, as well as, its potential use a more ..
Table of Contents
Depositor Specified Assays
Show more |
| AID | Name | Type | Comment |
|---|---|---|---|
| 588727 | A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83 | confirmatory | Primary and Confirmatory Assays |
| 602241 | A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83 (2) | confirmatory | Confirmatory (TC-83) |
| 602455 | A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83 (3) | confirmatory | Confirmatory (TC-83) |
| 624063 | A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV TC-83 (4) | confirmatory | Confirmatory (TC-83) |
| 624284 | On Hold | ||
| 624449 | On Hold | ||
| 651734 | On Hold | ||
| 651917 | On Hold | ||
| 602242 | A Cell-Based Counter Screen testing Compounds that Inhibit VEEV TC-83, in strain KU V3526 | confirmatory | Counter (v3586) |
| 651884 | On Hold | ||
| 602484 | A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, Trinidad Donkey (TrD) (1) | confirmatory | Confirmatory (Trinidad Donkey) |
| 651874 | On Hold | ||
| 588719 | Vero 76 Cytoxicity Assay for VEEV Compounds | confirmatory | Cytotoxicity counter screen (Vero 76) |
| 602240 | Vero 76 Cytoxicity Assay for VEEV Compounds (2) | confirmatory | Cytotoxicity counter screen (Vero 76) |
| 602439 | Vero 76 Cytoxicity Assay for VEEV Compounds (3) | confirmatory | Cytotoxicity counter screen (Vero 76) |
| 624069 | Vero 76 Cytoxicity Assay for VEEV Compounds (5) | confirmatory | Cytotoxicity counter screen (Vero 76) |
| 624295 | On Hold | ||
| 624450 | On Hold | ||
| 651735 | On Hold | ||
| 651930 | On Hold | ||
| 602307 | Virus Titer Reduction Secondary Screen for Compounds that Inhibit VEEV (TC-83 strain) | other | Virus Titer Reduction (TC-83) |
| 624286 | On Hold | ||
| 651578 | On Hold | ||
| 651886 | On Hold | ||
| 602411 | Virus Titer Reduction Secondary Screen for Compounds that Inhibit VEEV (2) Trinidad donkey strain | other | Virus Titer Reduction (Trinidad Donkey) |
| 651883 | On Hold | ||
| 602470 | A Counter Screen of Venezuelan Equine Encephalitis Virus (VEEV) Inhibitors in a Cell-Based Anti-Respiratory Syncytial Virus (RSV) Assay | confirmatory | RSV |
| 651932 | On Hold | ||
| 602483 | HEp2 Cytoxicity Assay for VEEV Compounds (1) | confirmatory | Cytotoxicity counter screen (Hep-2) |
| 623935 | A Cell-Based Secondary Assay for Compounds that Inhibit VEEV, TC-83 and other Alphaviruses (Chikungunya virus) | confirmatory | CHIKV |
| 651738 | On Hold | ||
| 651934 | On Hold | ||
| 623936 | Vero 76 Cytoxicity Assay for VEEV Compounds (4) | confirmatory | Cytotoxicity counter screen (Vero 76) |
Description:
Southern Research's Specialized Biocontainment Screening Center (SRSBSC)
Southern Research Institute (Birmingham, Alabama)
NIH Molecular Libraries Probe Production Centers Network (MLPCN)
Assay Provider: Dong Hoon Chung, University of Louisville
Award: 1 R03 MH087448-01A1
This project seeks to discover small molecules active in inhibiting replication of Venezuelan Equine Encephalitis Viruses (VEEV), by utilizing a high throughput screening (HTS) campaign from the Molecular Library Program Center Network (MLPCN). VEEV, an encephalitic alphavirus, is listed as a select agent for its ability to cause severe disease during epidemics, as well as, its potential use a bioterrorism weapon. However, there is no FDA-approved treatment or prophylaxis of VEEV-related diseases at this time. Antiviral drug discovery for select agents has been impractical due to restrictions on handling the agents. Hence, successful outcomes from this project will benefit the public and the military.
According to the first specific aim for the project, the primary and confirmatory screening campaign utilized an attenuated VEEV strain, TC-83, that produced a robust cytopathic effect in Vero76 cells and narrowed the focus of the >300K MLSMR library to a subset of compounds. The attenuated strain has a significantly high homology between its genome sequence (99.9% homology with 11 mutations in 11,443 base pairs) and the wild type VEEV and therefore the probability for the hits evaluated in this assay would be active for wild type VEEV as well. The secondary assays described below address the requirements for specificity and selectivity as highlighted in specific aim 2 for this project and further delineate the compounds and scaffolds that will be further pursued through medicinal chemistry.
Southern Research Institute (Birmingham, Alabama)
NIH Molecular Libraries Probe Production Centers Network (MLPCN)
Assay Provider: Dong Hoon Chung, University of Louisville
Award: 1 R03 MH087448-01A1
This project seeks to discover small molecules active in inhibiting replication of Venezuelan Equine Encephalitis Viruses (VEEV), by utilizing a high throughput screening (HTS) campaign from the Molecular Library Program Center Network (MLPCN). VEEV, an encephalitic alphavirus, is listed as a select agent for its ability to cause severe disease during epidemics, as well as, its potential use a bioterrorism weapon. However, there is no FDA-approved treatment or prophylaxis of VEEV-related diseases at this time. Antiviral drug discovery for select agents has been impractical due to restrictions on handling the agents. Hence, successful outcomes from this project will benefit the public and the military.
According to the first specific aim for the project, the primary and confirmatory screening campaign utilized an attenuated VEEV strain, TC-83, that produced a robust cytopathic effect in Vero76 cells and narrowed the focus of the >300K MLSMR library to a subset of compounds. The attenuated strain has a significantly high homology between its genome sequence (99.9% homology with 11 mutations in 11,443 base pairs) and the wild type VEEV and therefore the probability for the hits evaluated in this assay would be active for wild type VEEV as well. The secondary assays described below address the requirements for specificity and selectivity as highlighted in specific aim 2 for this project and further delineate the compounds and scaffolds that will be further pursued through medicinal chemistry.
Additional Information
Grant Number: 1 R03 MH087448-01A1
PageFrom: